Zentalis reports $392M cash; on track for azenosertib monotherapy dose, ASCO data

Zentalis Pharmaceuticals, Inc.

Cash, cash equivalents and marketable securities of $392M as of March 31, 2023; runway into Q2 2025.
R&D expenses $48.6M (up $2.5M YoY); G&A expenses $16.4M (up $4.6M YoY), with lease impairment charges.
On track to disclose azenosertib monotherapy dose in 1H 2023; positive Phase 1b chemo combo data in ovarian cancer at ASCO June 5.
Appointed Diana Hausman, M.D. to Board of Directors; Funda Meric-Bernstam, M.D. to Scientific Advisory Board.
ZN-d5 interim data in AL amyloidosis expected 2H 2023; Phase 1/2 combo with azenosertib in AML preliminary data also 2H 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Zentalis Pharmaceuticals, Inc. reported financial results for quarter ended March 31, 2023.

Period: quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 10, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2023 and commented on certain business updates. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-23-000112

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.